Skip to main content
Veterinary Medicines

Ingelvac PRRS MLV vacina de vírus vivo atenuado contra o síndroma reprodutivo e respiratório dos suínos (prrs), formas reprodutiva e respiratória.

Authorised
  • Porcine reproductive and respiratory syndrome virus, type 2, strain ATCC VR 2332, Live

Product identification

Medicine name:
Ingelvac PRRS MLV vacina de vírus vivo atenuado contra o síndroma reprodutivo e respiratório dos suínos (prrs), formas reprodutiva e respiratória.
Active substance:
  • Porcine reproductive and respiratory syndrome virus, type 2, strain ATCC VR 2332, Live
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Porcine reproductive and respiratory syndrome virus, type 2, strain ATCC VR 2332, Live
    4.90
    tissue culture infective dose 50
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for solution for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AD03
Authorisation status:
  • Valid
Authorised in:
  • Portugal
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Boehringer Ingelheim Vetmedica GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Vetmedica GmbH
Responsible authority:
  • Directorate General For Food And Veterinary
Authorisation number:
  • 541/95 DGV
Date of authorisation status change:

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Portuguese (PDF)
Published on: 31/10/2023
Updated on: 1/11/2023
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."